Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

| More on:
A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week.

Three ASX shares that brokers have named as buys this week are listed below. Here's why their analysts are feeling bullish on them right now:

Audinate Group Ltd (ASX: AD8)

According to a note out of Morgan Stanley, its analysts have retained their overweight rating on this audiovisual network technology company's shares with a heavily reduced price target of $10.00. This follows the release of its FY 2024 result this week. Although the broker was pleased with Audinate's strong performance in FY 2024, it was bitterly disappointed with its guidance for the year ahead. Its analysts highlight that management is guiding to lower profits, whereas the consensus estimate was for growth greater than 20%. But with its shares crashing and Morgan Stanley confident that structural growth drivers remain in place, it is holding firm with its overweight rating and appears to see this as a buying opportunity. The Audinate share price is trading at $8.37 on Wednesday.

Pro Medicus Limited (ASX: PME)

A note out of Goldman Sachs reveals that its analysts have retained their buy rating and $148.00 price target on this health imaging technology company's shares. Goldman is predicting another strong result from Pro Medicus this month. It expects revenue to rise 28% and EBITDA to be up 29%. The latter is a touch ahead of consensus estimates. And looking ahead, the broker is forecasting Pro Medicus' growth to accelerate in FY 2025. This is expected to be underpinned by a full period contribution of recent implementations, new contract wins, subsequent price increases, and negligible customer churn. The Pro Medicus share price is fetching $123.28 at the time of writing.

ResMed Inc. (ASX: RMD)

Analysts at Morgans have retained their add rating on this sleep disorder treatment company's shares with an improved price target of $35.93. This follows the release of a fourth quarter update that delivered on the market's expectations. Morgan was particularly pleased with ResMed's gross margin improvement and good cost control. In response, its analysts have boosted their earnings estimates and valuation accordingly. As a result, it thinks now could be a good time to snap up its shares. The ResMed share price is trading at $33.41 this afternoon.

Motley Fool contributor James Mickleboro has positions in Pro Medicus and ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Audinate Group, Goldman Sachs Group, Pro Medicus, and ResMed. The Motley Fool Australia has positions in and has recommended Audinate Group and ResMed. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
Broker Notes

How this undervalued ASX All Ords share could rocket 80% in a year

A leading fund manager expects a big turnaround for this beaten-down ASX All Ords stock.

Read more »

A car dealer stands amid a selection of cars parked in a showroom.
Broker Notes

Up 77% in a year, guess how much more upside Macquarie tips for Eagers Automotive shares

Macquarie released its latest analysis on Eagers Automotive fast rising shares this morning.

Read more »

Frustrated and shocked business woman reading bad news online from phone.
Broker Notes

Guess which ASX 200 share Goldman Sachs just downgraded

The broker is calling time on this stock's rally.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

These ASX 200 shares can rise 20% to 50%

Let's see which shares are being tipped to rocket from current levels.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Broker Notes

Why Guzman Y Gomez shares are a sell

Goldman Sachs has given its verdict on the burrito seller.

Read more »

A man pulls a shocked expression with mouth wide open as he holds up his laptop.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A couple makes silly chip moustache faces and take a selfie on their phone.
Broker Notes

Macquarie sees more upside in Telstra shares – What are they worth?

Telstra shares are up 34% over the past year, and Macquarie thinks there's more to come.

Read more »

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Broker Notes

What is Morgans saying about TechnologyOne, Wesfarmers, and Xero shares?

Let's see what the broker is saying about these shares.

Read more »